Ted Buchan & Co Makes New Investment in iShares Biotechnology ETF (NASDAQ:IBB)

Posted by Defense World Staff on Oct 1st, 2024

Ted Buchan & Co bought a new position in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 2,810 shares of the financial services provider’s stock, valued at approximately $386,000.

Other large investors have also recently added to or reduced their stakes in the company. Future Financial Wealth Managment LLC acquired a new stake in iShares Biotechnology ETF in the first quarter worth $27,000. Bbjs Financial Advisors LLC acquired a new stake in iShares Biotechnology ETF in the second quarter worth $31,000. Pacifica Partners Inc. increased its position in iShares Biotechnology ETF by 118.2% in the first quarter. Pacifica Partners Inc. now owns 240 shares of the financial services provider’s stock worth $33,000 after buying an additional 130 shares during the period. YHB Investment Advisors Inc. acquired a new stake in iShares Biotechnology ETF in the first quarter worth $37,000. Finally, Mather Group LLC. bought a new position in shares of iShares Biotechnology ETF in the first quarter worth $57,000. 62.45% of the stock is owned by institutional investors and hedge funds.

iShares Biotechnology ETF Price Performance

NASDAQ:IBB opened at $145.60 on Tuesday. iShares Biotechnology ETF has a 1 year low of $111.83 and a 1 year high of $150.57. The business has a fifty day moving average of $145.69 and a 200-day moving average of $138.91.

iShares Biotechnology ETF Announces Dividend

The firm also recently declared a dividend, which was paid on Monday, September 30th. Stockholders of record on Wednesday, September 25th were paid a $0.2005 dividend. The ex-dividend date of this dividend was Wednesday, September 25th.

iShares Biotechnology ETF Profile

(Free Report)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.